News

Press Releases

Nov 23, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 22, 2021

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

Nov 16, 2021

CRISPR Therapeutics and ViaCyte, Inc. to Start Clinical Trial of the First Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes

Nov 03, 2021

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2021 Financial Results

Presentations

Nov 23, 2021

CRISPR Therapeutics Corporate Presentation

Nov 23, 2021

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Nov 22, 2021

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell malignancies

Nov 16, 2021

CRISPR Therapeutics and ViaCyte to Start Clinical Trial of the First Gene Edited Cell Replacement

View All Presentations

Events

Wednesday, June 13, 2018 8:00 a.m. PT

CRISPR Therapeutics at Goldman Sachs 39th Annual Global Healthcare Conference

You are now leaving the CRISPR Therapeutics website.

CRISPR Therapeutics is not responsible for the content or availability of third-party sites.